INSTITUTIONAL REVIEW BOARD (IRB)/ INDEPENDENT ETHICS COMMITTEE (IEC)

 DEFINITION:

An independent group made up of members with backgrounds in medicine, science, and non-science, whose job is to ensure the rights, safety, and well-being of people taking part in clinical trials. They do this by reviewing, approving, and providing an ongoing review of the trial protocol and any amendments. The review procedures should comply with the Declaration of Helsinki and all other applicable international biomedical research norms.

To clarify its duties, each IRB/IEC Panel has its own set of written operational protocols. It should ensure that each subject during a clinical test receives appropriate and adequate care, to protect the confidentiality of subjects, and ensure the payment or compensation procedures. 


BACKGROUND:

In the 1960s, the first ECs for research were developed. An independent committee must be consulted before conducting any experiment involving humans, according to the first amendment of the Declaration of Helsinki (DOH), which was published in 1975. The requirement for EC approval of all clinical trials was once again highlighted in the US-drafted Belmont report in 1979. International ethical standards for biomedical research involving human subjects were developed by the Council for International Organization of Medical Sciences (CIOMS) in 2002. A new set of CT rules for 2019 has been published by DCGI.

A "Policy Statement on Ethical Considerations involved in Research on Human Subjects" was published in India by the Indian Council of Medical Research (ICMR) in February 1980. The guidelines were revised in 2006, and 2013 and the latest version was released in 2018.


RESPONSIBILITIES OF IRB/IEC:

  1. To protect the welfare, safety, and rights of test subject

  2. To review protocols within time.

  3. Should communicate their opinions in writing.

  4. Should conduct the continuous reviewing process.

  5. Special care should be taken for the trials that include vulnerable subjects.

  6. Address the necessity of informed consent

  • About written materials and documentation.
  • Compliance with regulatory requirements.
  • Communication with LAR.
  • Should enquire for more details.
  • About the amount and payment methods.
vii. Review of trial documents.


COMPOSITION OF IRB/IEC:

An IEC is made up of the institutional head and is a multidisciplinary, autonomous body. The number of people is limited (8 – 12). The IRB/IEC picks a chairperson from among its members who should not be the head of an analogous institution and should be from outside the institution. As a result, the committee's business is handled by the Member Secretary of an equivalent institution.

There must be a minimum of five people present to form a quorum or to conduct a meeting. According to the 2005 amendment to the 2005 revision of Schedule Y of the 1940 Medicine and Cosmetics Act, they should include a fundamental medical expert (pharmacologist), a doctor, one retired judge or a legal professional, one social scientist, one NGO representative, one philosopher, one ethicist, one theologian, or an identical person, and one layperson.

Members of IRB/IEC:



  According to the 2019 CT New Rules, IRB/IEC must be registered with CDSCO and DHR and follow its Standard Operating Procedures (SOPs). Periodic updates to these SOPs guarantee continued seamless operation. IEC's duties include ensuring that universal ethical values and international scientific standards are expressed, protecting the dignity, rights, and well-being of potential research participants, and assisting in the growth and education of a research community responsive to regional health care needs.

PROCEDURES OF IRB/IEC:

The IRB/IEC should adopt, formally record, and adhere to its policies, which ought to include:

1.     Establishing its members (members' identities and qualifications) and the legal framework that founded it.

2.     The planning, announcement, and conduct of its meetings.

3.     Doing a preliminary and ongoing analysis of studies.

4.    Stating that no subject should be allowed to participate in a trial until the IRB/IEC has given their formal approval or favorable assessment of the trial.

5.  Specifying that the following should be immediately reported by the investigator to the IRB/IEC:

(a) Deviations from the protocol or adjustments made to it to remove any urgent risks to the trial patients.

(b) Modifications that make individuals more at risk and/or materially impact how the experiment is conducted

(c) All severe and unanticipated adverse drug reactions (ADRs).

MAINTAINANCE OF RECORDS:

After the trial is finished, the IRB/IEC must keep all pertinent records (such as written procedures, membership lists, lists of members' occupations and affiliations, submitted documents, meeting minutes, and correspondence) for at least three years and make them available to regulatory authorities upon request.

CONCLUSION:

This blog mainly focuses on the IRB/IEC composition, its responsibilities, and its procedures. IRB/IEC effectiveness is dependent on- the quality and dedication of members; procedures; design documents; institutional commitment, financial resources, degree of independence, and investigator adherence to standards.

 

REFERENCES:

1.https://www.crc.gov.my/wpcontent/uploads/documents/intranet/GCP/04_IRB_Independent_EthicsCommittee_27102017.pdf

2.http://www.jirb.org.tw/DB/File/Download/970127-08_Role%20of%20IRB_Cristina%20Torres.pdf

3. https://globalresearchonline.net/journalcontents/v63-2/03.pdf




SUBMITTED BY:

B. AKSHITHA REDDY

PHARM-D

akshithaburugu@gmail.com

CSRPL_INT_OFL_WKD_154/0822


Comments

Popular Posts